TLR2 and acute myeloid leukemia: Moreover, CX-01 was successfully used to treat patients with acute myeloid leukemia (AML) when combined with standard therapy (consisting of cytarabine and idarubicin), giving a complete remission rate of 92% in a pilot study (NCT02995655) and of 89% in a randomized phase II trial conducted in elderly patients (NCT02873338), suggesting that TLR2 antagonists may potentiate the efficacy of standard AML induction therapy [128].